Dr. Brajenovic is a biopharmaceutical professional with over 18 years of drug development experience building and leading teams. Dr. Brajenovic was previously Head of Project and Alliance Management at Cell Design Labs (acquired by Kite/Gilead), where he was accountable to the Executive Team and Board of Directors for strategic leadership and operational oversight of the Cell Design Labs cell therapy portfolio and external alliances. Before that, he worked as Director Project Management at Medivation (acquired by Pfizer), where he was responsible for the broad development and commercialization of the PARP inhibitor Talzenna (Talazoparib). Prior to joining Medivation, Dr. Brajenovic worked for 10 years at Genentech (acquired by Roche), where he held positions of increasing leadership and management responsibilities in R&D, Portfolio and Project Management and Business Development, while gaining significant drug development experience and contributing to the growth and success of the pipeline. Earlier in his career, Dr. Brajenovic worked at a startup company, Cellzome (acquired by GSK), where he helped build the company, publish in top-tier journals and advance projects in a fast-paced environment.
Dr. Brajenovic holds a Ph.D. in Biology from University of Heidelberg, Germany. He was a Postdoctoral Fellow at Genentech and European Molecular Biology Laboratory (EMBL) in Heidelberg.